FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Brian Dean

Research Profile

Disorders

Chemicals & Drugs

Procedures

Anatomy

Living Beings

Rats

Co-author Network

Publications

TOP 3
Elizabeth Scarr; Jung Yoon Um; Tiffany Frances Cowie; Brian Dean
Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia.
Brian Dean
Epigenetic mechanisms and the serotonin 2A receptor in schizophrenia.
Andrew Stuart Gibbons; Won-Je Jeon; Tammie Money; Elizabeth Scarr; Simone Boer; Chris Felder; Brian Dean
Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Brian Dean (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Elizabeth Scarr; Jung Yoon Um; Tiffany Frances Cowie; Brian Dean
Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia.
Schizophrenia research 2013;146(1-3):279-84.
2013: Brian Dean
Epigenetic mechanisms and the serotonin 2A receptor in schizophrenia.
Schizophrenia research 2013;145(1-3):128-9.
2013: Andrew Stuart Gibbons; Won-Je Jeon; Tammie Money; Elizabeth Scarr; Simone Boer; Chris Felder; Brian Dean
Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2013;16(1):37-46.
2013: Elizabeth Scarr; Madhara Udawela; Andrew S Gibbons; Jaclyn Neo; Brian Dean
Cholinergic connectivity: it's implications for psychiatric disorders.
Frontiers in cellular neuroscience 2013;7():55.
2013: Elizabeth Scarr; M S Seo; B Weinrich; N J Beveridge; M J Cairns; A P Carroll; J M Craig; J C Galati; A Gibbons; S Juzva; M Parkinson-Bates; Richard Saffery; Brian Dean
Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA.
Translational psychiatry 2013;3():e230.
2012: Anna Bromberg; Brian Dean; Richard Ebstein; Elad Lerer; Elizabeth Scarr; Madhara Udawela; R H Belmaker; Galila Agam
Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic association and decreased frontal cortex mRNA levels.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2012;15(6):727-37.
2012: Elizabeth Scarr; Suresh Sundram; Renee Testa; Stephen J Wood; Azita Deljo; Andrew Stuart Gibbons; Susan Juzva; Andrew Mackinnon; Christos Pantelis; Tiffany Francis Cowie; Brian Dean
Muscarinic M1 receptor sequence: preliminary studies on its effects on cognition and expression.
Schizophrenia research 2012;138(1):94-8.
2012: Brian Dean
Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
Current pharmaceutical biotechnology 2012;13(8):1563-71.
2012: Elizabeth Scarr; Brian Dean
Altered neuronal markers following treatment with mood stabilizer and antipsychotic drugs indicate an increased likelihood of neurotransmitter release.
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2012;10(1):25-33.
2012: Andrew Stuart Gibbons; Elizabeth Scarr; Lucy Brooks; Brian Dean
AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder.
Journal of affective disorders 2012;136(3):1232-7.
2012: Brian Dean
Neurochemistry of schizophrenia: the contribution of neuroimaging postmortem pathology and neurochemistry in schizophrenia.
Current topics in medicinal chemistry 2012;12(21):2375-92.
2012: Elizabeth Scarr; Tammie Terese Money; Jaclyn Neo; Geoffrey Pavey; Brian Dean
Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study.
BMC psychiatry 2012;12():126.
2011: Brian Dean
Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2011;14(7):997-1012.
2011: Madhara Udawela; Elizabeth Scarr; Anthony J Hannan; Elizabeth A Thomas; Brian Dean
Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness.
The Australian and New Zealand journal of psychiatry 2011;45(2):140-7.
2011: Brian Dean
Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers.
Schizophrenia research and treatment 2011;2011():614730.
2011: Andrew Stuart Gibbons; Madhara Udawela; Won Je Jeon; Myoung Suk Seo; Lucy Brooks; Brian Dean
The neurobiology of APOE in schizophrenia and mood disorders.
Frontiers in bioscience : a journal and virtual library 2011;16():962-79.
2011: Michael Berk; Flávio Kapczinski; A C Andreazza; O M Dean; F Giorlando; M Maes; Murat Yucel; C S Gama; S Dodd; Brian Dean; P V S Magalhães; P Amminger; Patrick McGorry; Gin S Malhi
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.
Neuroscience and biobehavioral reviews 2011;35(3):804-17.
2010: Adel Barakat; Brian Dean; Elizabeth Scarr; Geneviève Evin
Decreased Neuregulin 1 C-terminal fragment in Brodmann's area 6 of patients with schizophrenia.
Schizophrenia research 2010;124(1-3):200-7.
2010: Mark C McLeod; Elizabeth Scarr; Brian Dean
Effects of benzodiazepine treatment on cortical GABA(A) and muscarinic receptors: studies in schizophrenia and rats.
Psychiatry research 2010;179(2):139-46.
2010: Laura Gray; Brian Dean; Helena C Kronsbein; Phillip J Robinson; Elizabeth Scarr
Region and diagnosis-specific changes in synaptic proteins in schizophrenia and bipolar I disorder.
Psychiatry research 2010;178(2):374-80.
2010: Simone Boer; Diego Sanchez; Ivo Reinieren; Tom van den Boom; Madhara Udawela; Elizabeth Scarr; Maria D Ganfornina; Brian Dean
Decreased kainate receptors in the hippocampus of apolipoprotein D knockout mice.
Progress in neuro-psychopharmacology & biological psychiatry 2010;34(2):271-8.
2010: Andrew Stuart Gibbons; Elizabeth A Thomas; Elizabeth Scarr; Brian Dean
Low Density Lipoprotein Receptor-Related Protein and Apolipoprotein E Expression is Altered in Schizophrenia.
Frontiers in psychiatry / Frontiers Research Foundation 2010;1():19.
2010: Brian Dean; Nahed Tawadros; Elizabeth Scarr; Andrew S Gibbons
Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder.
Journal of affective disorders 2010;120(1-3):245-8.
2009: Simone Boer; Michael Berk; Brian Dean
Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder.
Neuroscience letters 2009;466(1):27-9.
2009: Elizabeth Scarr; T F Cowie; S Kanellakis; S Sundram; Christos Pantelis; Brian Dean
Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia.
Molecular psychiatry 2009;14(11):1017-23.
2009: Alex Fornito; Murat Yucel; Brian Dean; Stephen J Wood; Christos Pantelis
Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology.
Schizophrenia bulletin 2009;35(5):973-93.
2009: Laura Gray; Caitlin E McOmish; Elizabeth Scarr; Brian Dean; Anthony J Hannan
Sensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2009;12(7):917-28.
2009: A S Gibbons; Elizabeth Scarr; C McLean; Suresh Sundram; Brian Dean
Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects.
Journal of affective disorders 2009;116(3):184-91.
2009: A S Gibbons; Elizabeth A Thomas; Brian Dean
Regional and duration of illness differences in the alteration of NCAM-180 mRNA expression within the cortex of subjects with schizophrenia.
Schizophrenia research 2009;112(1-3):65-71.
2009: Nicholas A Keks; Christine Hill; Suresh Sundram; Annette Graham; Kylee Bellingham; Brian Dean; Kenneth Opeskin; Arrigo Dorissa; David Copolov
Evaluation of treatment in 35 cases of bipolar suicide.
The Australian and New Zealand journal of psychiatry 2009;43(6):503-8.
2009: Brian Dean; Simone Boer; Andrew Gibbons; Tammie Money; Elizabeth Scarr
Recent advances in postmortem pathology and neurochemistry in schizophrenia.
Current opinion in psychiatry 2009;22(2):154-60.
2009: Elizabeth Scarr; Brian Dean
Role of the cholinergic system in the pathology and treatment of schizophrenia.
Expert review of neurotherapeutics 2009;9(1):73-86.
2008: Elizabeth Scarr; Brian Dean
Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
Journal of neurochemistry 2008;107(5):1188-95.
2008: Brian Dean; Andrew Soulby; Geneviève M Evin; Elizabeth Scarr
Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1.
Schizophrenia research 2008;106(2-3):229-36.
2008: Brian Dean; Geoffrey Pavey; A Ian Smith
Using differential solubilization and 2-D gel electrophoresis to visualize increased numbers of proteins in the human cortex and caudate nucleus and putamen.
Proteomics. Clinical applications 2008;2(9):1281-9.
2008: Brian Dean; Nicola Crossland; Simone Boer; Elizabeth Scarr
Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia.
Schizophrenia research 2008;104(1-3):185-97.
2008: Laura Gray; Caitlin McOmish; Elizabeth Scarr; Brian Dean; Anthony J Hannan
Role of muscarinic receptors in the activity of N-desmethylclozapine: reversal of hyperactivity in the phospholipase C knockout mouse.
Behavioural pharmacology 2008;19(5-6):543-7.
2008: Andrew Stuart Gibbons; Elizabeth Scarr; Caitlin E McOmish; Anthony J Hannan; Elizabeth A Thomas; Brian Dean
Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia.
The Australian and New Zealand journal of psychiatry 2008;42(8):740-5.
2008: C E McOmish; E Burrows; M Howard; Elizabeth Scarr; D Kim; H-S Shin; Brian Dean; Maarten van den Buuse; Anthony J Hannan
Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration.
Molecular psychiatry 2008;13(7):661-72.
2008: Brian Dean; Alison Digney; Suresh Sundram; Elizabeth Thomas; Elizabeth Scarr
Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder.
Psychiatry research 2008;158(1):75-8.
2008: Mark C McLeod; Suresh Sundram; Brian Dean
Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain.
Progress in neuro-psychopharmacology & biological psychiatry 2008;32(2):560-7.
2008: Brian Dean; Tim Karl; Geoffrey Pavey; Simone Boer; Liesl Duffy; Elizabeth Scarr
Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice.
Schizophrenia research 2008;99(1-3):341-9.
2007: Brian Dean; Simone A Boer; Andrew Mackinnon; Michael Berk
CNS 14-3-3zeta: changes with sex but not psychiatric diagnoses or psychotropic drug treatment.
Schizophrenia research 2007;93(1-3):51-7.
2007: Elizabeth Scarr; Suresh Sundram; Dahlia Keriakous; Brian Dean
Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia.
Biological psychiatry 2007;61(10):1161-70.
2007: Brian Dean; Dahlia Keriakous; Elizabeth Scarr; Elizabeth A Thomas
Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia.
The Australian and New Zealand journal of psychiatry 2007;41(4):308-20.
2006: Brian Dean; Geoffrey Pavey; David Thomas; Elizabeth Scarr
Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment.
Schizophrenia research 2006;88(1-3):265-74.
2006: Avril Pereira; Brian Dean
Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis.
Biochemical pharmacology 2006;72(6):783-93.
2006: Laura Gray; Elizabeth Scarr; Brian Dean
Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder.
Psychiatry research 2006;143(2-3):111-20.
2006: Elizabeth Scarr; Laura Gray; Dahlia Keriakous; P J Robinson; Brian Dean
Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder.
Bipolar disorders 2006;8(2):133-43.
2006: Brian Dean; Laura Gray; Elizabeth Scarr
Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia.
The Australian and New Zealand journal of psychiatry 2006;40(3):217-24.
2006: Elizabeth Scarr; Dahlia Keriakous; Nicola Crossland; Brian Dean
No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia.
Life sciences 2006;78(11):1231-7.
2006: Laura Gray; Elizabeth Scarr; Brian Dean
N-Ethylmaleimide sensitive factor in the cortex of subjects with schizophrenia and bipolar I disorder.
Neuroscience letters 2006;391(3):112-5.
2005: Brian Dean; Elizabeth Scarr; Mark McLeod
Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder.
Brain research. Molecular brain research 2005;138(2):145-55.
2005: Suresh Sundram; David Copolov; Brian Dean
Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens.
Naunyn-Schmiedeberg's archives of pharmacology 2005;371(5):428-33.
2005: Alison Digney; Dahlia Keriakous; Elizabeth Scarr; Elizabeth Thomas; Brian Dean
Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder.
Biological psychiatry 2005;57(7):711-5.
2004: Elizabeth Scarr; Geoffrey Pavey; David Copolov; Brian Dean
Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects.
Schizophrenia research 2004;71(2-3):383-92.
2004: Margaret J Smith; Robyn A Sharples; Geneviève Evin; Catriona A McLean; Brian Dean; Geoffrey Pavey; Emmanuelle Fantino; Richard G H Cotton; Kazunori Imaizumi; Colin L Masters; Roberto Cappai; Janetta G Culvenor
Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex.
Brain research. Molecular brain research 2004;127(1-2):128-35.
2004: Brian Dean; Elizabeth Scarr
Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.
Current drug targets. CNS and neurological disorders 2004;3(3):217-25.
2004: Brian Dean; Geoffrey Pavey; Elizabeth Scarr; K Goeringer; David Copolov
Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia.
Life sciences 2004;74(25):3115-31.
2004: Brian Dean
The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissue.
The Australian and New Zealand journal of psychiatry 2004;38(3):135-40.
2003: Elizabeth Scarr; Geoffrey Pavey; Suresh Sundram; Andrew Mackinnon; Brian Dean
Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder.
Bipolar disorders 2003;5(4):257-64.
2003: Brian Dean
[3H]RX 821002 in human dorsolateral prefrontal cortex: no changes in postmortem tissue from subjects with schizophrenia.
Psychiatry research 2003;119(1-2):25-31.
2003: Brian Dean; Elizabeth Scarr; Geoffrey Pavey; David Copolov
Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder.
Journal of affective disorders 2003;75(1):65-9.
2003: Brian Dean; Robyn Bradbury; David Copolov
Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia.
Biological psychiatry 2003;53(7):585-92.
2003: Brian Dean
The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice.
Journal of neurochemistry 2003;85(1):1-13.
2002: Mark McLeod; Daniele Pralong; David Copolov; Brian Dean
The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem.
Brain research. Molecular brain research 2002;104(2):203-9.
2002: Brian Dean
Changes in the molecular structure of the brain in bipolar disorder: findings using human postmortem brain tissue.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2002;3(3):125-32.
2002: Geoffrey Pavey; David Copolov; Brian Dean
High-resolution phosphor imaging: validation for use with human brain tissue sections to determine the affinity and density of radioligand binding.
Journal of neuroscience methods 2002;116(2):157-63.
2002: Elizabeth Scarr; Fiona-Marie Parkin; Geoffrey Pavey; Brian Dean
Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats.
Life sciences 2002;70(22):2699-705.
2002: Mark McLeod; Daniele Pralong; David Copolov; Brian Dean
[(3)H]Flumazenil binding in the human hippocampal formation, frontal cortex and cerebellum detected by high-resolution phosphorimaging.
Brain research 2002;926(1-2):27-32.
2002: Brian Dean; M McLeod; Dahlia Keriakous; J McKenzie; Elizabeth Scarr
Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia.
Molecular psychiatry 2002;7(10):1083-91.
2002: Elizabeth Scarr; Geoffrey Pavey; P J Robinson; Kenneth Opeskin; David Copolov; Brian Dean
Decreased phorbol ester binding in the parahippocampal gyrus from subjects with schizophrenia is not associated with changes in protein kinase C.
Molecular psychiatry 2002;7(7):683-8.
2001: Brian Dean; Geoffrey Pavey; Mark McLeod; Kenneth Opeskin; Nicholas A Keks; David Copolov
A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder.
Journal of affective disorders 2001;66(2-3):147-58.
2001: Brian Dean; T Hussain; Elizabeth Scarr; Geoffrey Pavey; David Copolov
Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum.
Life sciences 2001;69(11):1257-68.
2001: Jeremy M Crook; E Tomaskovic-Crook; David Copolov; Brian Dean
Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment.
The American journal of psychiatry 2001;158(6):918-25.
2001: Brian Dean; Suresh Sundram; Robyn Bradbury; Elizabeth Scarr; David Copolov
Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.
Neuroscience 2001;103(1):9-15.
2001: Brian Dean
A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia.
Clinical and experimental pharmacology & physiology 2001;28(1-2):74-8.
2000: Brian Dean
Schizophrenia: an illness of distorted reality.
Biologist (London, England) 2000;47(4):202-6.
2000: Jeremy M Crook; E Tomaskovic-Crook; David Copolov; Brian Dean
Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.
Biological psychiatry 2000;48(5):381-8.
2000: Brian Dean
Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia.
The Australian and New Zealand journal of psychiatry 2000;34(4):560-9.
2000: Daniele Pralong; E Tomaskovic-Crook; Kenneth Opeskin; David Copolov; Brian Dean
Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia.
Schizophrenia research 2000;44(1):35-45.
2000: Brian Dean; Jeremy M Crook; Geoffrey Pavey; Kenneth Opeskin; David Copolov
Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia.
Molecular psychiatry 2000;5(2):203-7.
1999: Brian Dean; Elizabeth Scarr; Robyn Bradbury; David Copolov
Decreased hippocampal (CA3) NMDA receptors in schizophrenia.
Synapse (New York, N.Y.) 1999;32(1):67-9.
1999: Brian Dean; E Tomaskovic-Crook; Kenneth Opeskin; Nicholas A Keks; David Copolov
No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia.
Neurochemistry international 1999;34(2):109-15.
1999: Jeremy M Crook; Brian Dean; Geoffrey Pavey; David Copolov
The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia.
Life sciences 1999;64(19):1761-71.
1998: L Naylor; Brian Dean; A Pereira; Andrew Mackinnon; A Kouzmenko; David Copolov
No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus.
Molecular medicine (Cambridge, Mass.) 1998;4(10):671-4.
1998: D Farnbach-Pralong; Robyn Bradbury; David Copolov; Brian Dean
Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors.
European journal of pharmacology 1998;349(2-3):R7-8.
1998: S B Roberts; C A Hill; Brian Dean; Nicholas A Keks; Kenneth Opeskin; David Copolov
Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience.
The Australian and New Zealand journal of psychiatry 1998;32(1):73-6.
1997: Brian Dean; A Pereira; Geoffrey Pavey; B Singh
Repeated antidepressant drug treatment, time of death and frequency of handling do not affect [3H]paroxetine binding in rat cortex.
Psychiatry research 1997;73(3):173-9.
1997: Brian Dean; Geoffrey Pavey; Kenneth Opeskin
[3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects.
Neuropharmacology 1997;36(6):779-86.
1997: Brian Dean; Kenneth Opeskin; Geoffrey Pavey; C Hill; Nicholas A Keks
Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia.
Journal of neural transmission (Vienna, Austria : 1996) 1997;104(11-12):1371-81.
1996: Kenneth Opeskin; Brian Dean; Geoffrey Pavey; C Hill; Nicholas A Keks; David Copolov
Neither protein kinase C nor adenylate cyclase are altered in the striatum from subjects with schizophrenia.
Schizophrenia research 1996;22(2):159-64.
1996: Brian Dean; W Hayes
Decreased frontal cortical serotonin2A receptors in schizophrenia.
Schizophrenia research 1996;21(3):133-9.
1996: S Sundram; Brian Dean; David Copolov
Typical and atypical neuroleptic drugs decrease platelet 3H-dopamine uptake in the rat.
Psychiatry research 1996;62(3):259-63.
1996: Brian Dean; J M Crook; Kenneth Opeskin; C Hill; Nicholas A Keks; David Copolov
The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia.
Molecular psychiatry 1996;1(1):54-8.
1996: D C Wan; Brian Dean; Geoffrey Pavey; David Copolov
Treatment with haloperidol or clozapine causes changes in dopamine receptors but not adenylate cyclase or protein kinase C in the rat forebrain.
Life sciences 1996;59(23):2001-8.
1996: Brian Dean; S Sundram; C Hill; D L Copolov
Platelet [3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder.
Progress in neuro-psychopharmacology & biological psychiatry 1996;20(1):45-55.
1996: L Naylor; Brian Dean; Kenneth Opeskin; Geoffrey Pavey; C Hill; Nicholas A Keks; David Copolov
Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine.
Journal of neural transmission (Vienna, Austria : 1996) 1996;103(6):749-57.
1996: Brian Dean; W Hayes; Kenneth Opeskin; L Naylor; Geoffrey Pavey; C Hill; Nicholas A Keks; David Copolov
Serotonin2 receptors and the serotonin transporter in the schizophrenic brain.
Behavioural brain research 1996;73(1-2):169-75.
1995: Brian Dean; Kenneth Opeskin; Geoffrey Pavey; L Naylor; C Hill; Nicholas A Keks; David Copolov
[3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia.
Journal of neurochemistry 1995;64(3):1197-202.
1994: S Sundram; Brian Dean; David Copolov
The development of a method to measure [3H] dopamine uptake by washed platelets provides no evidence for circulating inhibitors of platelet dopamine uptake in schizophrenia.
Biological psychiatry 1994;36(9):595-600.
1992: Brian Dean; A J McAdam; S Sundram; Geoffrey Pavey; L C Harrison; David Copolov
Identification of a dopamine-binding protein on the membrane of the human platelet.
The Biochemical journal 1992;287 ( Pt 1)():45-50.
1989: Brian Dean; D L Copolov
Dopamine uptake by the human platelet: effects of dopamine receptor agonists.
European journal of pharmacology 1989;173(2-3):165-9.
1989: Brian Dean; David Copolov
Dopamine uptake by platelets is selective, temperature dependent and not influenced by the dopamine-D1 or dopamine-D2 receptor.
Life sciences 1989;45(5):401-11.